• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

    9/30/24 8:00:00 AM ET
    $EXAI
    $RLYB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EXAI alert in real time by email

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. ASBMR is being held September 27 – 30, 2024 in Toronto, Canada.

    "From my team's earlier work published in 2002 and 2005, we knew that ENPP1 could be a targetable molecule to modulate TNAP's all-important substrate PPi. I am delighted that we have now been able to demonstrate the efficacy of this principle in our mouse model of later-onset HPP," said José Luis Millán, Ph.D., Professor, Human Genetics Program at Sanford Children's Health Research Center, Sanford Burnham Prebys Medical Discovery Institute, and author of the study.

    HPP is a rare, genetic, metabolic disorder characterized by poor bone mineralization. The disease has a broad spectrum of symptoms and severity ranging from the life-threatening perinatal- and infantile-onset form to the less severe juvenile-onset form that can manifest with frequent bone fractures, significant joint and bone pain, and joint swelling. HPP is caused by loss-of-function mutations in the gene that encodes tissue-nonspecific alkaline phosphatase (TNAP), whose deficiency results in the accumulation of extracellular inorganic pyrophosphate (PPi), an inhibitor of bone mineralization.

    "The data presented at ASBMR supports ENPP1 inhibition as a therapeutic approach for patients with hypophosphatasia," said Stephen Uden, MD, Chief Executive Officer of Rallybio. "There is significant unmet patient need in HPP, particularly in adults. We believe this data with an early lead ENPP1 inhibitor from our joint venture with Exscientia is very promising and gives us enthusiasm that the development candidate we expect to nominate in the fourth quarter could be a safe and effective treatment to meaningfully improve the lives of patients suffering from HPP."

    This nonclinical study was designed to assess whether ENPP1 could be a druggable target to treat the non-lethal forms of HPP using an early lead ENPP1 inhibitor and the Alpl-/Prx1 mouse, which is a model of later-onset HPP.

    Results indicate that oral dosing of an early lead ENPP1 inhibitor, REV101, to adult HPP mice lowered PPi by 30%, leading to improvements in mineralization of long and vertebrate bones. Furthermore, data showed that ENPP1 inhibition was safe and well-tolerated, and, for the first time, showed that ENPP1 is a druggable target for later-onset HPP.

    Rallybio and Exscientia plc (NASDAQ:EXAI) are developing an ENPP1 inhibitor with improved properties compared with REV101 as a differentiated therapy to address the unmet need in patients with HPP. Rallybio and Exscientia expect to nominate a development candidate in the fourth quarter of 2024.

    Details of yesterday's poster presentation:

    Title: ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia

    Date/Time: September 29, 2024, 2:15pm – 3:45pm EDT

    Presenter: Dr. José Luis Millán

    Poster Number: Sun-LB 552

    The poster will be available in the Publications & Presentations section of Rallybio's website following the conclusion of the conference.

    About Rallybio

    Rallybio (NASDAQ:RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on our management's beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the timing of development candidate nomination for Rallybio' ENPP1 inhibitor, whether Rallybio's small molecule would successfully inhibit ENPP1, or demonstrate efficacy in later-onset HPP, or otherwise be safe when administered to humans. The forward-looking statements in this press release are only predictions and are based largely on management's current expectations and projections about future events and financial trends that management believes may affect Rallybio's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 2 clinical trial for RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio's filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio's Quarterly Report on Form 10-Q for the period ended June 30, 2024, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240927040487/en/

    Get the next $EXAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAI
    $RLYB

    CompanyDatePrice TargetRatingAnalyst
    Rallybio Corporation
    $RLYB
    4/9/2025Buy → Neutral
    H.C. Wainwright
    Exscientia Plc
    $EXAI
    7/9/2024Buy
    TD Cowen
    Rallybio Corporation
    $RLYB
    5/15/2024Overweight → Neutral
    JP Morgan
    Rallybio Corporation
    $RLYB
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    Exscientia Plc
    $EXAI
    1/5/2024$11.00 → $9.00Buy → Neutral
    BofA Securities
    Rallybio Corporation
    $RLYB
    4/17/2023$18.00Buy
    H.C. Wainwright
    Rallybio Corporation
    $RLYB
    4/10/2023$17.00Outperform
    Wedbush
    Rallybio Corporation
    $RLYB
    12/9/2022$21.00Overweight
    JP Morgan
    More analyst ratings

    $EXAI
    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exscientia Plc

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      11/22/24 9:11:55 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Exscientia Plc

      SC 13D/A - Exscientia plc (0001865408) (Subject)

      11/22/24 8:00:16 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      11/12/24 10:34:15 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EXAI
    $RLYB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Rallybio Corporation

      10-Q - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:22:09 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rallybio Corp (0001739410) (Filer)

      5/8/25 8:14:12 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Rallybio Corp (0001739410) (Filer)

      4/8/25 8:25:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EXAI
    $RLYB
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

      Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

      8/8/24 7:39:25 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

      — AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia's internal oncology pipeline — Exscientia plc (NASDAQ:EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. Appointed to Chief Technology Officer, John P. Overington, Ph.D.,

      6/6/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parker Moss to Join Exscientia as EVP, Corporate Development

      Renowned technology champion to strengthen company's development of precision medicine and clinical innovation platforms Exscientia plc (NASDAQ:EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company's precision medicine, clinical and tech innovation platforms, with a particular focus on oncology. Reporting to CEO Andrew Hopkins, he will help the company's Executive Leadership Team to identify and shape new business opportuni

      10/17/23 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Uden Stephen

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:30:54 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ryder Steven

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:29:06 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Lieber Jonathan I

      4 - Rallybio Corp (0001739410) (Issuer)

      2/19/25 7:27:18 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EXAI
    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EXAI
    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

      – On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments. "We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe th

      5/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical-stage bi

      4/29/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

      – RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company's decision to discontinue RLYB212 development was based on pharmacokinetic (PK) data from the Phase 2 clinical trial demonstrating the inability of the R

      4/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Rallybio from Buy to Neutral

      4/9/25 8:36:28 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Exscientia plc

      TD Cowen initiated coverage of Exscientia plc with a rating of Buy

      7/9/24 7:31:11 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rallybio downgraded by JP Morgan

      JP Morgan downgraded Rallybio from Overweight to Neutral

      5/15/24 7:39:44 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EXAI
    $RLYB
    Financials

    Live finance-specific insights

    See more
    • Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

      Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R

      7/18/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Business Update for First Quarter 2024

      Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and streamlining operations to realise annualised savings of $40 million Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscient

      5/21/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

      Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 (800) 358 0970 (U.K.), +1 (646) 960 0857 (International)

      5/14/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care